Across imaging modalities, measures of either neurodegenerative changes (atrophy, glucose hypometabolism, or tau accumulation) or vascular injury (WMH or SVD composite measures) were reported to correlate with higher CDR-SB or predict steeper AD progression (Kamal et al., 2023; Yang et al., 2023; Du et al., 2025). Here, MAPT is linked to Alzheimer disease.